INS and metabolic disease: Inositols indeed play a key role in the management of metabolic disorders, as evidenced by the literature, which has demonstrated the safety of the dosage of 4 g of inositols in their 40:1 ratio in dysmetabolic patients, highlighting their insulin-sensitizing effect [2,3,4].